Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor.

[1]  D. Kay,et al.  Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2]  J. Taylor-Cousar,et al.  Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  S. Rowe,et al.  Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[5]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[6]  E. Stringer,et al.  Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[7]  S. Borrero,et al.  Attitudes and Decision Making Related to Pregnancy Among Young Women with Cystic Fibrosis , 2017, Maternal and Child Health Journal.